Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APTO Aptose Biosciences	$1.71	$4.41	$1.35 ▼ $50.10	$3.66M	1.04	227,964 shs	N/A
DBVT DBV Technologies	$19.73 -1.3%	$20.78	$7.53 ▼ $26.18	$1.10B	-0.96	307,011 shs	127,428 shs
MESO Mesoblast	$14.74 -0.4%	$15.20	$9.88 ▼ $21.50	$1.91B	2.09	241,878 shs	100,788 shs
SRRK Scholar Rock	$48.39 +4.2%	$46.15	$27.07 ▼ $51.63	$5.77B	0.7	1.33 million shs	1.05 million shs
VCEL Vericel	$33.46 -4.8%	$33.93	$28.95 ▼ $45.97	$1.70B	1.15	597,711 shs	1.26 million shs

Beginner's Guide To Retirement Stocks

Click the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APTO Aptose Biosciences	0.00%	0.00%	0.00%	0.00%	0.00%
DBVT DBV Technologies	-0.55%	-4.81%	-2.25%	-5.97%	+110.42%
MESO Mesoblast	-6.39%	-5.55%	+8.11%	-7.21%	+33.94%
SRRK Scholar Rock	-1.50%	-0.34%	-6.91%	-2.46%	+56.40%
VCEL Vericel	-4.49%	+1.15%	+5.40%	-2.93%	-13.26%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APTO Aptose Biosciences	$1.71	$4.41	$1.35 ▼ $50.10	$3.66M	1.04	227,964 shs	N/A
DBVT DBV Technologies	$19.73 -1.3%	$20.78	$7.53 ▼ $26.18	$1.10B	-0.96	307,011 shs	127,428 shs
MESO Mesoblast	$14.74 -0.4%	$15.20	$9.88 ▼ $21.50	$1.91B	2.09	241,878 shs	100,788 shs
SRRK Scholar Rock	$48.39 +4.2%	$46.15	$27.07 ▼ $51.63	$5.77B	0.7	1.33 million shs	1.05 million shs
VCEL Vericel	$33.46 -4.8%	$33.93	$28.95 ▼ $45.97	$1.70B	1.15	597,711 shs	1.26 million shs

Beginner's Guide To Retirement Stocks

Click the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APTO Aptose Biosciences	0.00%	0.00%	0.00%	0.00%	0.00%
DBVT DBV Technologies	-0.55%	-4.81%	-2.25%	-5.97%	+110.42%
MESO Mesoblast	-6.39%	-5.55%	+8.11%	-7.21%	+33.94%
SRRK Scholar Rock	-1.50%	-0.34%	-6.91%	-2.46%	+56.40%
VCEL Vericel	-4.49%	+1.15%	+5.40%	-2.93%	-13.26%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APTO Aptose Biosciences	0.00	N/A	N/A	N/A
DBVT DBV Technologies	2.67	Moderate Buy	$40.25	104.68% Upside
MESO Mesoblast	2.33	Hold	N/A	N/A
SRRK Scholar Rock	3.17	Buy	$56.00	17.35% Upside
VCEL Vericel	2.63	Moderate Buy	$55.40	65.69% Upside

Current Analyst Ratings Breakdown

Latest SRRK, VCEL, MESO, DBVT, and APTO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/8/2026	SRRK Scholar Rock	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$53.00 ➝ $55.00
5/8/2026	SRRK Scholar Rock	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$58.00 ➝ $65.00
5/8/2026	VCEL Vericel	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$64.00
5/4/2026	DBVT DBV Technologies	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$51.00
5/1/2026	DBVT DBV Technologies	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
5/1/2026	DBVT DBV Technologies	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Outperform	$47.00 ➝ $55.00
4/21/2026	MESO Mesoblast	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
4/21/2026	SRRK Scholar Rock	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
4/20/2026	SRRK Scholar Rock	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$62.00
4/20/2026	SRRK Scholar Rock	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
4/15/2026	VCEL Vericel	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$48.00 ➝ $42.00

(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APTO Aptose Biosciences	N/A	N/A	N/A	N/A	($0.19) per share	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	$3.73 per share	N/A
MESO Mesoblast	$65.38M	29.19	N/A	N/A	$4.67 per share	3.16
SRRK Scholar Rock	N/A	N/A	N/A	N/A	$2.41 per share	N/A
VCEL Vericel	$276.26M	6.16	$0.50 per share	66.21	$7.01 per share	4.77

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APTO Aptose Biosciences	-$51.21M	-$89.19	N/A	N/A	N/A	N/A	-5,683.22%	-300.44%	N/A
DBVT DBV Technologies	-$146.95M	-$4.46	N/A	N/A	N/A	-2,895.37%	-129.88%	-88.84%	N/A
MESO Mesoblast	-$102.14M	-$0.54	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SRRK Scholar Rock	-$377.94M	-$3.59	N/A	N/A	N/A	N/A	-145.91%	-96.68%	N/A
VCEL Vericel	$16.52M	$0.31	108.01	43.42	N/A	5.98%	5.17%	3.67%	N/A

Latest SRRK, VCEL, MESO, DBVT, and APTO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2026	Q1 2026	SRRK Scholar Rock	-$0.82	-$0.83	-$0.01	-$0.83	$5.00 million	N/A
5/7/2026	Q1 2026	VCEL Vericel	-$0.15	-$0.12	+$0.03	-$0.12	$63.68 million	$68.43 million
4/30/2026	Q4 2025	DBVT DBV Technologies	-$0.14	-$0.56	-$0.42	-$0.55	$1.11 million	$0.90 million
3/26/2026	Q4 2025	DBVT DBV Technologies	-$0.1935	-$1.15	-$0.9565	-$4.43	$1.06 million	$0.64 million
3/3/2026	Q4 2025	SRRK Scholar Rock	-$0.86	-$0.76	+$0.10	-$0.76	N/A	N/A
2/26/2026	Q4 2025	VCEL Vericel	$0.45	$0.45	N/A	$0.45	$92.66 million	$92.92 million
2/14/2026	Q4 2025	DBVT DBV Technologies	N/A	-$1.15	N/A	-$1.15	N/A	$0.65 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
APTO Aptose Biosciences	N/A	N/A	N/A	N/A	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
MESO Mesoblast	N/A	N/A	N/A	N/A	N/A
SRRK Scholar Rock	N/A	N/A	N/A	N/A	N/A
VCEL Vericel	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APTO Aptose Biosciences	N/A	1.05	1.05
DBVT DBV Technologies	N/A	4.76	4.76
MESO Mesoblast	0.10	1.58	1.41
SRRK Scholar Rock	0.41	6.95	6.95
VCEL Vericel	N/A	5.03	4.68

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APTO Aptose Biosciences	26.62%
DBVT DBV Technologies	71.74%
MESO Mesoblast	1.43%
SRRK Scholar Rock	91.08%
VCEL Vericel	N/A

Insider Ownership

Company	Insider Ownership
APTO Aptose Biosciences	1.33%
DBVT DBV Technologies	1.44%
MESO Mesoblast	18.80%
SRRK Scholar Rock	13.30%
VCEL Vericel	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APTO Aptose Biosciences	31	2.14 million	63.45 million	No Data
DBVT DBV Technologies	80	55.67 million	54.87 million	Optionable
MESO Mesoblast	80	129.46 million	105.12 million	Optionable
SRRK Scholar Rock	140	119.30 million	103.44 million	Optionable
VCEL Vericel	300	50.93 million	47.06 million	Optionable

SRRK, VCEL, MESO, DBVT, and APTO Headlines

Recent News About These Companies

Vericel (NASDAQ:VCEL) Trading Down 9.1% - What's Next?

3 hours ago | marketbeat.com

Vericel Corporation (VCEL) Q1 2026 Earnings Call Transcript

May 7 at 12:00 AM | seekingalpha.com

Vericel (NASDAQ:VCEL) Posts Earnings Results, Beats Estimates By $0.03 EPS

May 7 at 11:04 PM | marketbeat.com

Vericel Corporation (VCEL) Reports Q1 Loss, Beats Revenue Estimates

May 7 at 12:16 PM | zacks.com

Vericel (NASDAQ:VCEL) Shares Gap Up on Strong Earnings

May 7 at 10:19 AM | marketbeat.com

Vericel Corporation Reports 30% Revenue Growth to $68.4 Million in Q1 2026, Raises Full-Year Guidance to $326-$336 Million

May 7 at 8:11 AM | quiverquant.comQ

Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance

May 7 at 7:45 AM | globenewswire.com

Vericel Q1 2026 earnings preview

May 7 at 3:43 AM | msn.com

Wall Street Analysts Think Vericel (VCEL) Could Surge 53.42%: Read This Before Placing a Bet

May 4, 2026 | zacks.com

Vericel Corporation (NASDAQ:VCEL) Receives $55.40 Average PT from Analysts

May 3, 2026 | americanbankingnews.com

Vericel Shareholders Reaffirm Board, Pay Plan, Auditor

May 1, 2026 | tipranks.com

Conestoga Capital Advisors LLC Acquires 79,278 Shares of Vericel Corporation $VCEL

May 1, 2026 | marketbeat.com

Vericel Annual Meeting: Shareholders Elect Seven Directors, Approve Say-on-Pay and PwC Auditor

May 1, 2026 | marketbeat.com

Vericel (VCEL) Expected to Announce Earnings on Thursday

April 30, 2026 | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Given Consensus Recommendation of "Moderate Buy" by Brokerages

April 28, 2026 | marketbeat.com

Vericel to Report First-Quarter 2026 Financial Results on May 7, 2026

April 23, 2026 | globenewswire.com

Vericel (NASDAQ:VCEL) Shares Down 7.1% - Time to Sell?

April 21, 2026 | marketbeat.com

Insider Selling: Vericel (NASDAQ:VCEL) Insider Sells 3,472 Shares of Stock

April 7, 2026 | insidertrades.com

Vericel Gets $197M U.S. Government Contract for Burn Treatment

April 2, 2026 | marketwatch.com

MediWound and Vericel Secure Up to $197 Million BARDA Contract for NexoBrid® Procurement and Development

April 2, 2026 | quiverquant.comQ

Vericel Announces BARDA Award Valued at up to $197 Million for Procurement and Advanced Development of NexoBrid

April 2, 2026 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRRK, VCEL, MESO, DBVT, and APTO Company Descriptions

Aptose Biosciences NASDAQ:APTO

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

DBV Technologies NASDAQ:DBVT

$19.73 -0.26 (-1.30%)

Closing price 04:00 PM Eastern

Extended Trading

$19.73 0.00 (0.00%)

As of 04:04 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Mesoblast NASDAQ:MESO

$14.74 -0.06 (-0.41%)

Closing price 04:00 PM Eastern

Extended Trading

$14.74 0.00 (0.00%)

As of 04:10 PM Eastern

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Scholar Rock NASDAQ:SRRK

$48.39 +1.94 (+4.18%)

Closing price 04:00 PM Eastern

Extended Trading

$48.41 +0.02 (+0.04%)

As of 04:10 PM Eastern

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Vericel NASDAQ:VCEL

$33.46 -1.67 (-4.75%)

Closing price 04:00 PM Eastern

Extended Trading

$33.45 -0.01 (-0.03%)

As of 04:40 PM Eastern

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SRRK, VCEL, MESO, DBVT, and APTO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SRRK, VCEL, MESO, DBVT, and APTO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SRRK, VCEL, MESO, DBVT, and APTO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRRK, VCEL, MESO, DBVT, and APTO Company Descriptions

Aptose Biosciences NASDAQ:APTO

DBV Technologies NASDAQ:DBVT

Mesoblast NASDAQ:MESO

Scholar Rock NASDAQ:SRRK

Vericel NASDAQ:VCEL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SRRK, VCEL, MESO, DBVT, and APTO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SRRK, VCEL, MESO, DBVT, and APTO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SRRK, VCEL, MESO, DBVT, and APTO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRRK, VCEL, MESO, DBVT, and APTO Company Descriptions

Aptose Biosciences NASDAQ:APTO

DBV Technologies NASDAQ:DBVT

Mesoblast NASDAQ:MESO

Scholar Rock NASDAQ:SRRK

Vericel NASDAQ:VCEL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools